Business
StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.
StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc..
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nStockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.\n\nStockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.\n\n\n LOS ANGELES, CA--(Marketwired - December 14, 2015) - \n StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Gerald Commissiong, President and CEO of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing product candidates in Regenerative Medicine and Orphan Diseases, according to the Company's website\n(see here: www.Amarantus.com). The video interview was recorded at the LD Micro \"Main Event\" on December 2nd, 2015 in Bel Air, CA.Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:\n Year-End Review with Amarantus BioScience Holdings, Inc. -- Discusses Severe Burns, Parkinson's Clinical Trials, MANF Pre-Clinical Work and Diagnostics\n You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITSPlease review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer\n About Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings (OTCQX: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of adult severe burns currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas. AMBS also has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa ...